Reply to D. Tural et al

J Clin Oncol. 2014 Jul 20;32(21):2274. doi: 10.1200/JCO.2014.55.7199. Epub 2014 Jun 9.

Authors

Laurent Azoulay¹, Oriana Yu², Samy Suissa³

Affiliations

¹ Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital; McGill University, Montreal, Quebec, Canada laurent.azoulay@mcgill.ca.
² Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
³ Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital; McGill University, Montreal, Quebec, Canada.

PMID: 24912889
DOI: 10.1200/JCO.2014.55.7199

No abstract available

Publication types

Comment

MeSH terms

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Male
Prostatic Neoplasms / diagnosis*
Prostatic Neoplasms / mortality*

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors